Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Other Operating Expenses (2024 - 2025)

Intellia Therapeutics (NTLA) has disclosed Other Operating Expenses for 2 consecutive years, with $1.8 million as the latest value for Q4 2025.

  • Quarterly Other Operating Expenses rose 102.83% to $1.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$899000.0 through Dec 2025, up 97.24% year-over-year, with the annual reading at -$899000.0 for FY2025, 97.24% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $1.8 million at Intellia Therapeutics, up from -$3.4 million in the prior quarter.
  • The five-year high for Other Operating Expenses was $20.4 million in Q2 2024, with the low at -$62.0 million in Q4 2024.